Skip to main content
SpringerLink
Log in

Cellular Therapy for Follicular Lymphoma

  • Chapter
  • First Online:
Follicular Lymphoma

  • 551 Accesses

Abstract

Despite major advances in the treatment of follicular lymphoma, the disease generally remains incurable. Novel targeted agents often require prolonged or continuous administration with issues of cost, compliance, and cumulative toxicity. Autologous stem cell transplantation results in very prolonged remissions and cure in up to 50% of patients with chemotherapy-sensitive recurrence. Recent data indicate that salvage autologous transplantation leads to improved survival for patients with early treatment failure, i.e., recurrence within 2 years after appropriate initial treatment. It may be the preferred treatment for such patients. Autologous transplantation has also been extensively investigated in the consolidation treatment of younger patients with high-risk features but has largely been abandoned in that setting because of concerns over late therapy-related MDS/AML. Purging techniques to reduce graft contamination have been associated with decreased rates of disease recurrence after autologous transplantation, as has posttransplant rituximab maintenance. Allogeneic transplantation has low rates of disease recurrence but a higher rate of complications, despite widespread use of reduced intensity conditioning. Haplo-transplant, umbilical cord blood transplant, or haplo-cord transplants are excellent graft sources for those lacking HLA-identical donors. For transformed lymphoma, autologous transplant improves survival. Novel cellular therapies including CAR-T therapy are playing an increasing role in the management of transformed B-cell lymphoma and will likely also find a role follicular lymphoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Frei E 3rd, Teicher BA, Holden SA, Cathcart KN, Wang YY. Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res. 1988;48(22):6417–23.

    CAS  PubMed  Google Scholar 

  2. Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med. 1991;325:1525–33.

    Article  CAS  PubMed  Google Scholar 

  3. Rohatiner AZS, Price CGA, Amott S, et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation of remission in patients with follicular lymphoma. Ann Oncol. 1991;2(suppl2):147.

    PubMed  Google Scholar 

  4. Rohatiner AZ, Nadler L, Davies AJ, Apostolidis J, Neuberg D, Matthews J, et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol. 2007;25(18):2554–9.

    Article  PubMed  Google Scholar 

  5. Armitage JO. Myelodysplasia and acute leukemia after autologous bone marrow transplantation. J Clin Oncol. 2000;18(5):945–6.

    Article  CAS  PubMed  Google Scholar 

  6. Abruzzese E, Radford JE, Miller JS, Vredenburgh JJ, Rao PN, Pettenati MJ, et al. Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation. Blood. 1999;94(5):1814–9.

    CAS  PubMed  Google Scholar 

  7. Chao NJ, Nademanee AP, Long GD, Schmidt GM, Donlon TA, Parker P, et al. Importance of bone marrow cytogenetic evaluation before autologous bone marrow transplantation for Hodgkin’s disease. J Clin Oncol. 1991;9:1575–9.

    Article  CAS  PubMed  Google Scholar 

  8. Montoto S, Canals C, Rohatiner AZ, Taghipour G, Sureda A, Schmitz N, et al. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia. 2007;21(11):2324–31.

    Article  CAS  PubMed  Google Scholar 

  9. Kornacker M, Stumm J, Pott C, Dietrich S, Sussmilch S, Hensel M, et al. Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up. Ann Oncol. 2009;20(4):722–8.

    Article  CAS  PubMed  Google Scholar 

  10. Peters AC, Duan Q, Russell JA, Duggan P, Owen C, Stewart DA. Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score. Leuk Lymphoma. 2011;52(11):2124–9.

    Article  CAS  PubMed  Google Scholar 

  11. Kothari J, Peggs KS, Bird A, Thomson KJ, Morris E, Virchis AE, et al. Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure. Br J Haematol. 2014;165(3):334–40.

    Article  CAS  PubMed  Google Scholar 

  12. Jimenez-Ubieto A, Grande C, Caballero D, Yanez L, Novelli S, Hernandez-Garcia MT, et al. Autologous stem cell transplantation for follicular lymphoma: favorable long-term survival irrespective of pretransplantation rituximab exposure. Biol Blood Marrow Transplant. 2017;23(10):1631–40.

    Article  PubMed  Google Scholar 

  13. Micallef IN, Lillington DM, Apostolidis J, Amess JA, Neat M, Matthews J, et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol. 2000;18(5):947–55.

    Article  CAS  PubMed  Google Scholar 

  14. Tarella C, Passera R, Magni M, Benedetti F, Rossi A, Gueli A, et al. Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol. 2011;29(7):814–24.

    Article  CAS  PubMed  Google Scholar 

  15. Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnson HE, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003;21(21):3918–27.

    Article  CAS  PubMed  Google Scholar 

  16. Vose JM, Carter S, Burns LJ, Ayala E, Press OW, Moskowitz CH, et al. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol. 2013;31(13):1662–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Bento L, Boumendil A, Finel H, Le Gouill S, Amorim S, Monjanel H, et al. Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (autologous transplant) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party. Bone Marrow Transplant. 2017;52(8):1120–5.

    Article  CAS  PubMed  Google Scholar 

  18. Lenz G, Dreyling M, Schiegnitz E, Forstpointner R, Wandt H, Freund M, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood. 2004;104(9):2667–74.

    Article  CAS  PubMed  Google Scholar 

  19. Sebban C, Mounier N, Brousse N, Belanger C, Brice P, Haioun C, et al. Standard chemotherapy with interferon compared to CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the GELA. Blood. 2006;108(8):2540–4.

    Article  CAS  PubMed  Google Scholar 

  20. Deconinck E, Foussard C, Milpied N, Bertrand P, Michenet P, Cornillet-LeFebvre P, et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood. 2005;105(10):3817–23.

    Article  CAS  PubMed  Google Scholar 

  21. Gyan E, Foussard C, Bertrand P, Michenet P, Le Gouill S, Berthou C, et al. High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood. 2009;113(5):995–1001.

    Article  CAS  PubMed  Google Scholar 

  22. Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood. 2008;111(8):4004–13.

    Article  CAS  PubMed  Google Scholar 

  23. Al Khabori M, de Almeida JR, Guyatt GH, Kuruvilla J, Crump M. Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2012;104(1):18–28.

    Article  PubMed  Google Scholar 

  24. Montoto S, Corradini P, Dreyling M, Ghielmini M, Kimby E, Lopez-Guillermo A, et al. Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. Haematologica. 2013;98(7):1014–21.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Gribben JG, Nadler LM. Detection of minimal residual disease in patients with lymphomas using the polymerase chain reaction. [review]. Important Adv Oncol. 1994;13:117–29.

    Google Scholar 

  26. Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009;27(36):6101–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Liu H, Johnson JL, Koval G, Malnassy G, Sher D, Damon LE, et al. Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909. Haematologica. 2012;97(4):579–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Bierman P, Sweetenham J, Loberiza F, Taghipour G, Lazarus H, Rizzo J, et al. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin’s lymphoma: a comparison with allogeneic and autologous transplantation – the lymphoma working committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2003;21(20):3744–53.

    Article  PubMed  Google Scholar 

  29. van Besien K, Loberiza FR, Bajorunaite R, Armitage JO, Bashey A, Burns LJ, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003;102(10):3521–9.

    Article  PubMed  CAS  Google Scholar 

  30. Belhadj K, Hicheri Y, Pautas C. Benefit of the adjunction of rituximab in salvage regimen before autologous stem cell transplantation in follicular lymphoma at relapse. A single institution study. Blood. 2005;106(11):2075a.

    Article  Google Scholar 

  31. Arcaini L, Orlandi E, Alessandrino EP, Iacona I, Brusamolino E, Bonfichi M, et al. A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma. Bone Marrow Transplant. 2004;34(2):175–9.

    Article  CAS  PubMed  Google Scholar 

  32. Arcaini L, Montanari F, Alessandrino EP, Tucci A, Brusamolino E, Gargantini L, et al. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. Ann Oncol. 2008;19(7):1331–5.

    Article  CAS  PubMed  Google Scholar 

  33. Pettengell R, Schmitz N, Gisselbrecht C, Smith G, Patton WN, Metzner B, et al. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2013;31(13):1624–30.

    Article  CAS  PubMed  Google Scholar 

  34. Smyth L, Buckstein R, Pennell N, Weerasinghe R, Cheung MC, Imrie K, et al. Autologous stem cell transplant and combination immunotherapy of rituximab and interferon-alpha induces prolonged clinical and molecular remissions in patients with follicular lymphoma. Br J Haematol. 2018; https://doi.org/10.1111/bjh.15118. [Epub ahead of print].

    Article  PubMed  Google Scholar 

  35. Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005;23(33):8447–52.

    Article  CAS  PubMed  Google Scholar 

  36. Cheah CY, Fowler NH. Novel agents for relapsed and refractory follicular lymphoma. Best Pract Res Clin Haematol. 2018;31(1):41–8.

    Article  PubMed  Google Scholar 

  37. Casulo C, Friedberg JW, Ahn KW, Flowers C, DiGilio A, Smith SM, et al. Autologous transplantation in follicular lymphoma with early therapy failure: a National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transplant. 2018;24(6):1163–71.

    Article  PubMed  Google Scholar 

  38. Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33(23):2516–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Jurinovic V, Kridel R, Staiger AM, Szczepanowski M, Horn H, Dreyling MH, et al. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood. 2016;128(8):1112–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Jurinovic V, Metzner B, Pfreundschuh M, Schmitz N, Wandt H, Keller U, et al. Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of two randomized trials from the German Low Grade Lymphoma Study Group. Biol Blood Marrow Transplant. 2018;24(6):1172–9.

    Article  PubMed  Google Scholar 

  41. Manna M, Lee-Ying R, Davies G, Stewart C, Oh D, Peters A, et al. Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within 2-years of chemoimmunotherapy: a multicentre retrospective analysis of consecutively treated patients in the real world. Leuk Lymphoma. 2018;3:1–9. https://doi.org/10.1080/10428194.2018.1473576. [Epub ahead of print].

    Article  Google Scholar 

  42. Casulo C, Flowers CR. When to choose transplant in follicular lymphoma: navigating a complex landscape. J Oncol Pract. 2017;13(12):808–9.

    Article  PubMed  Google Scholar 

  43. Cheah CY, Nastoupil LJ, McLaughlin P, Fanale MA, Neelapu SS, Fayad LE, et al. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity. Br J Haematol. 2016;175(3):531–3.

    Article  CAS  PubMed  Google Scholar 

  44. Ghez D, Calleja A, Protin C, Baron M, Ledoux MP, Damaj G, et al. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 2018;131(17):1955–9.

    Article  CAS  PubMed  Google Scholar 

  45. Andresen S, Brandt J, Dietrich S, Memmer ML, Ho AD, Witzens-Harig M. The impact of high-dose chemotherapy, autologous stem cell transplant and conventional chemotherapy on quality of life of long-term survivors with follicular lymphoma. Leuk Lymphoma. 2012;53(3):386–93.

    Article  CAS  PubMed  Google Scholar 

  46. Vanbesien K, Khouri I, Giralt S, Mccarthy P, Mehra R, Andersson B, et al. Allogeneic bone-marrow transplantation for refractory and recurrent low-grade lymphoma – the case for aggressive management. J Clin Oncol. 1995;13(5):1096–102.

    Article  CAS  Google Scholar 

  47. Mandigers C, Meijerink JP, Raemaekers JM, Schattenberg A, Mensink EJ. Graft vs lymphoma effect of donor leucocyte infusions shown by real-time quantitative PCR analysis of t(14;18). Lancet. 1998;352:1522–3.

    Article  CAS  PubMed  Google Scholar 

  48. Van Besien KW, de Lima M, Giralt SA, Moore DFJ, Khouri I, Rondón G, et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effects. Bone Marrow Transplant. 1997;19:977–82.

    Article  PubMed  Google Scholar 

  49. van Besien K, Sobocinski K, Rowlings P, Murphy S, Armitage J, Bishop M, et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood. 1998;92(5):1832–6.

    PubMed  Google Scholar 

  50. Peniket AJ, Ruiz de Elvira MC, Taghipour G, Cordonnier C, Gluckman E, de Witte T, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant. 2003;31(8):667–78.

    Article  CAS  PubMed  Google Scholar 

  51. Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R, et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia. 2007;21(11):2316–23.

    Article  CAS  PubMed  Google Scholar 

  52. Hari P, Carreras J, Zhang MJ, Gale RP, Bolwell BJ, Bredeson CN, et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant. 2008;14(2):236–45.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 2008;111(12):5530–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, et al. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood. 2012;119(26):6373–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Bhatia S, Francisco L, Carter A, Sun CL, Baker KS, Gurney JG, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood. 2007;110(10):3784–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Boyiadzis M, Arora M, Klein JP, Hassebroek A, Hemmer M, Urbano-Ispizua A, et al. Impact of chronic graft-versus-host disease on late relapse and survival on 7,489 patients after myeloablative allogeneic hematopoietic cell transplantation for leukemia. Clin Cancer Res. 2015;21(9):2020–8.

    Article  PubMed  Google Scholar 

  57. Sureda A, Zhang MJ, Dreger P, Carreras J, Fenske T, Finel H, et al. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: a combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. Cancer. 2018;124(8):1733–42.

    Article  CAS  PubMed  Google Scholar 

  58. Morris E. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood. 2004;104(13):3865–71.

    Article  CAS  PubMed  Google Scholar 

  59. Thomson K, Morris E, Milligan D, Parker AN, Hunter AE, Cook G, et al. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol. 2010;28:3695–700.

    Article  PubMed  Google Scholar 

  60. Delgado J, Canals C, Attal M, Thomson K, Campos A, Martino R, et al. The role of in vivo T-cell depletion on reduced-intensity conditioning allogeneic stem cell transplantation from HLA-identical siblings in patients with follicular lymphoma. Leukemia. 2011;25(3):551–5.

    Article  CAS  PubMed  Google Scholar 

  61. Avivi I, Montoto S, Canals C, Maertens J, Al-Ali H, Mufti GJ, et al. Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Br J Haematol. 2009;147(5):719–28.

    Article  PubMed  Google Scholar 

  62. Rodrigues CA, Sanz G, Brunstein CG, Sanz J, Wagner JE, Renaud M, et al. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2009;27(2):256–63.

    Article  PubMed  Google Scholar 

  63. Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a Center for International Blood and Marrow Transplant Research Analysis. J Clin Oncol. 2016;34(26):3141–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Dietrich S, Finel H, Martinez C, Tischer J, Blaise D, Chevallier P, et al. Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation. Leukemia. 2016;30(10):2086–9.

    Article  CAS  PubMed  Google Scholar 

  65. van Besien K, Hari P, Zhang MJ, Liu HT, Stock W, Godley L, et al. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and survival free of progression and GVHD (GRFS). Haematologica. 2016;101(5):634–43.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  66. Hsu JM, Artz A, Mayer SA, Guarner D, Bishop MR, Reich-Slotky R, et al. Combined haploidentical and umbilical cord blood allogeneic stem cell transplantation for high-risk lymphoma and chronic lymphoblastic leukemia. Biol Blood Marrow Transplant. 2018;24(2):359–65.

    Article  PubMed  Google Scholar 

  67. Van Besien K, Artz A, Champlin RE, Guarneri D, Bishop M, Chen J, et al. Fludarabine melphalan conditioning followed by T-replete haplo identical (haplo) transplantation or haplo cord (HC) transplantation. Blood. 2017;130(Suppl 1):3328.

    Google Scholar 

  68. Van Besien KW, Hsu JM, Gergis U, Phillips A, Mayer S, Shore T. Cord blood transplantation supported by unrelated donor progenitor cells for patients without haplo identical relatives. Bone Marrow Transplant, 2017;52(Suppl 1):A177.

    Google Scholar 

  69. Godley LA, van Besien K. The next frontier for stem cell transplantation: finding a donor for all. JAMA. 2010;303(14):1421–2.

    Article  CAS  PubMed  Google Scholar 

  70. Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26(32):5165–9.

    Article  PubMed  Google Scholar 

  71. Villa D, Crump M, Keating A, Panzarella T, Feng B, Kuruvilla J. Outcome of patients with transformed indolent non-Hodgkin lymphoma referred for autologous stem-cell transplantation. Ann Oncol. 2013;24(6):1603–9.

    Article  CAS  PubMed  Google Scholar 

  72. Williams CD, Harrison CN, Lister TA, Norton AJ, Blystad AK, Coiffier B, et al. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin’s lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol. 2001;19(3):727–35.

    Article  CAS  PubMed  Google Scholar 

  73. Hamadani M, Benson DM Jr, Lin TS, Porcu P, Blum KA, Devine SM. High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. Eur J Haematol. 2008;81(6):425–31.

    Article  PubMed  Google Scholar 

  74. Friedberg JW, Neuberg D, Gribben JG, Mauch P, Anderson KC, Soiffer RJ, et al. Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. Biol Blood Marrow Transplant. 1999;5(4):262–8.

    Article  CAS  PubMed  Google Scholar 

  75. Chen CI, Crump M, Tsang R, Stewart AK, Keating A. Autotransplants for histologically transformed follicular non-Hodgkin’s lymphoma. Br J Haematol. 2001;113(1):202–8.

    Article  CAS  PubMed  Google Scholar 

  76. Hamadani M, Awan FT, Elder P, Lin TS, Porcu P, Benson DM, et al. Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. Leuk Lymphoma. 2008;49(10):1893–8.

    Article  PubMed  Google Scholar 

  77. Villa D, Crump M, Panzarella T, Savage KJ, Toze CL, Stewart DA, et al. Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group. J Clin Oncol. 2013;31(9):1164–71.

    Article  CAS  PubMed  Google Scholar 

  78. Wirk B, Fenske TS, Hamadani M, Zhang MJ, Hu ZH, Akpek G, et al. Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma. Biol Blood Marrow Transplant. 2014;20(7):951–9.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Brudno JN, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol. 2018;15(1):31–46.

    Article  CAS  PubMed  Google Scholar 

  80. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116(20):4099–102.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Neelapu SS, Tummala S, Kebriaei P, Wierda W, Locke FL, Lin Y, et al. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit ‘ALL’. Nat Rev Clin Oncol. 2018;15(4):218.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Locke FL, Anasetti C, Moffitt Immunotherapy Working G, the Immune Cell Therapy P. Transplanters drive CARs to the clinic by brewing ICE-T: the Moffitt roadmap. J Immunother Cancer. 2017;5(1):59.

    Google Scholar 

  83. Kosuri S, Van Besien KH. Stem cell transplantation in follicular lymphoma (Ch. 14). In: Savani BN, Mohty M, editors. Clinical guide to transplantation in lymphoma. Chichester/Hoboken: Wiley; 2015. Available from:http://BN7ZQ5YK2C.search.serialssolutions.com/?V=1.0&L=BN7ZQ5YK2C&S=JCs&C=TC0001515161&T=marc&tab=BOOKS.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology/Oncology, Weill Cornell Medical College/New York Presbyterian, New York, NY, USA

    Ok-kyong Chaekal & Koen van Besien

  2. Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Paolo Strati

Authors
  1. Ok-kyong Chaekal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paolo Strati
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Koen van Besien
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paolo Strati .

Editor information

Editors and Affiliations

  1. Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Nathan H. Fowler

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Chaekal, Ok., Strati, P., van Besien, K. (2020). Cellular Therapy for Follicular Lymphoma. In: Fowler, N. (eds) Follicular Lymphoma. Springer, Cham. https://doi.org/10.1007/978-3-030-26211-2_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-26211-2_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-26210-5

  • Online ISBN: 978-3-030-26211-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation